12/27/12

Thy roid Nodule

Medscape Reference Reference

News Reference Education MEDLINE

Thyroid Nodule
Author: Steven K Dankle, MD; Chief Editor: George T Griffing, MD more... Updated: Feb 28, 2012

Background
Nodular disease of the thyroid gland is prevalent in the United States. The lifetime risk for developing a palpable thyroid nodule is estimated to be 5-10%, and the condition affects more women than men.

A 12-year-old patient w ith an asymptomatic, palpable thyroid nodule, w hich w as noticed upon routine physical examination.

Surgical specimen of a thyroid lobe w ith papillary carcinoma, taken from a 12-year-old patient w ith an asymptomatic, palpable thyroid nodule; the nodule w as noticed upon routine physical examination.

1/8

12/27/12

Thy roid Nodule

Thyroid w ith a large goiter. The right lobe of the thyroid w as sectioned and reveals a large, solid nodule w ith necrotic and hemorrhagic areas. The histologic diagnosis w as follicular thyroid carcinoma.

In general, nodular disease of the thyroid is common; however, malignancy of the thyroid occurs in only 0.004% of the American population annually (12,000 new cases per y). Roughly 5% of thyroid nodules are malignant; the remainder represent a variety of benign diagnoses, including colloid nodules, degenerative cysts, hyperplasia, thyroiditis, or benign neoplasms. A rational approach to management of a thyroid nodule is based on the clinician's ability to distinguish the more common benign diagnoses from malignancy in a highly reliable and costeffective manner.

Recent studies
In a study of 261 patients undergoing surgical evaluation for thyroid disease, Mazzaglia investigated whether officebased, surgeon-performed ultrasonographic examination significantly effected operative treatment of the patients even though all of these individuals had previously undergone ultrasonographic thyroid examination. Mazzaglia reported that treatment plans for 46 patients (17.6%) were altered because of significant differences between outside and surgeon-administered ultrasonograms. In 12 patients, for example, previously unidentified nonpalpable, enlarged lymph nodes were found in the surgeon-administered ultrasonograms, with biopsy revealing metastatic thyroid cancer in 3 of these patients. Mazzaglia concluded that surgeon-performed ultrasonographic examinations can be used to make necessary changes in surgical treatment and to avoid unnecessary surgery.[1]

Clinical Outline
A comprehensive history and physical examination provides the foundation for decision making in the management of thyroid nodules. A number of features in the patient's history and physical examination significantly influence the statistical probability of malignancy in a thyroid nodule. Factors suggesting a malignant diagnosis include the following: Age younger than 20 years or older than 70 years Male sex Associated symptoms of dysphagia or dysphonia History of neck irradiation Prior history of thyroid carcinoma Firm, hard, or immobile nodule Presence of cervical lymphadenopathy Factors suggesting a benign diagnosis include the following: Family history of autoimmune disease (eg, Hashimoto thyroiditis) Family history of benign thyroid nodule or goiter Presence of thyroid hormonal dysfunction (eg, hypothyroidism, hyperthyroidism) Pain or tenderness associated with nodule Soft, smooth, and mobile nodule Of importance, the factors mentioned above are only guidelines to assist in decision-making, and they do not provide absolute diagnostic information. For example, a historical axiom is that a multinodular goiter without a dominant nodule or a solitary cyst suggests a benign diagnosis. Data from contemporary studies, including those incorporating image-guided fine-needle aspiration biopsy (FNAB), have raised questions about this axiom. Furthermore, the ultrasonographic size of a solid thyroid nodule may have some diagnostic importance, because nodules larger than 3 cm are thought to have an increased risk of malignancy. However, findings suggest that
emedicine.medscape.com/article/127491-ov erv iew 2/8

12/27/12

Thy roid Nodule

nonpalpable nodules (incidentalomas) incidentally found on high-resolution ultrasonography may have a risk of malignancy comparable to that of palpable nodules.

Diagnostic Workup
Laboratory evaluation
The most important laboratory test is a sensitive thyroid-stimulating hormone (TSH) assay, which is used to screen for hypothyroidism or hyperthyroidism. In addition, obtaining serum thyroxine (T4) and triiodothyronine (T3) levels may be helpful (eg, when TSH levels are low-normal or high-normal). In most cases of solitary thyroid nodules, the TSH level is normal. In cases of a solitary thyroid nodule with a normal TSH value, no additional laboratory studies may be required in the diagnostic evaluation unless autoimmune disease (eg, Hashimoto thyroiditis) is suspected. When the patient's history and physical findings reveal a family history or raise clinical suspicion for Hashimoto thyroiditis, obtain serum antithyroid peroxidase (anti-TPO) antibody and antithyroglobulin (anti-Tg) antibody levels. A diagnosis of Hashimoto thyroiditis does not exclude the possibility of malignancy. Additional laboratory studies are unnecessary in the routine initial diagnostic evaluation of a solitary thyroid nodule.

Imaging studies
Thyroid scintigraphy In most centers, the routine initial diagnostic evaluation of a solitary thyroid nodule no longer includes imaging studies. In the past, radionuclide scanning was an important imaging study performed routinely in the initial assessment of a thyroid nodule. Nuclear imaging can be used to describe a nodule as hot, warm, or cold on the basis of its relative uptake of radioactive isotope. Hot nodules indicate autonomously functioning nodules, warm nodules suggest normal thyroid function, and cold nodules indicate hypofunctional or nonfunctional thyroid tissue. (Examples of hot and cold nodules are seen in the image below.) Hot nodules are rarely malignant; however, 5-8% of warm or cold nodules are malignant.[2]

Technetium-99m (99mTc) thyroid scan of a large, nontoxic multinodular goiter. Multiple cold and hot nodules are observed in the enlarged thyroid gland. The w hite arrow indicates the sternal notch marker.

Ultrasonography Because of advances in technology, ultrasonography is highly sensitive in determining the size and number of thyroid nodules. By itself, ultrasonography cannot reliably be used to distinguish a benign nodule from a malignant nodule. However, combining high-resolution sonography with Doppler and spectral analysis of the vascular characteristics of a thyroid nodule holds promise as a useful tool in screening thyroid nodules for malignancy. Studies have shown that the risk of malignancy is lower in nodules with a predominantly perinodular pattern than in nodules with an exclusively central vascular pattern. Furthermore, if the vascular characteristics of thyroid nodules are combined with their ultrasonographic parameters, including a halo, microcalcifications, cross-sectional diameter, and echogenicity, the predictive value of this imaging approach may increase.[2, 3, 4, 5] A study by Sun et al found that osteopontin expression has a role in the microcalcification found in papillary thyroid carcinoma that is reflected on ultrasonography.[6]
emedicine.medscape.com/article/127491-ov erv iew 3/8

12/27/12

Thy roid Nodule

Thyroid ultrasonography can be helpful in certain cases when it is used to guide FNAB. Data have suggested that ultrasonography-guided FNAB may be preferable to palpation-guided FNAB.[7] Although sensitivity and specificity are not clearly and significantly between the approaches to FNAB, many authors consider image-guided FNAB to hold certain advantages. For example, image-guided FNAB may be particularly helpful in the assessment of nonpalpable or small nodules, nodules with cystic components, or nodules that are difficult to access (eg, posterior or substernal nodules). Ultrasonography-guided FNAB, combined with on-site cytologic verification of the adequacy of the specimen by a cytotechnologist or pathologist, may likely provide the highest sensitivity and specificity. Whether this is the most cost-effective approach for all thyroid nodules remains an issue. Computed tomography (CT) scanning, magnetic resonance imaging (MRI), and positron emission tomography (PET) scanning CT scanning or MRI is generally not cost-effective in the initial evaluation of solitary thyroid nodules. Such studies may be useful in the assessment of thyroid masses that are largely substernal. Also, in some cases CT scan guided FNAB may be helpful. PET scanning with 18F-fluorodeoxyglucose is at present primarily an investigational tool, but it might have some role in thyroid imaging in the future, particularly in the evaluation of metastatic disease.[8, 9] However, a study by Deandreis et al found PET scanning to offer no additional diagnostic benefit in the evaluation of a thyroid nodule that has been found to have indeterminate cytopathology on FNAB.[10] In the past, nuclear imaging studies of the thyroid, often combined with ultrasonography, were routinely performed in initial assessment of thyroid nodules. Because only 10% of solitary thyroid nodules are hot and because 90% of cold nodules are not malignant, nuclear imaging with or without ultrasonography typically offers a low yield of cancer diagnoses in surgical specimens when their results are used as the main guides for referral to a surgeon. Fine-needle aspiration biopsy FNAB has emerged as the most important step in the diagnostic evaluation of thyroid nodules.[11] Data from numerous studies have established FNAB as highly accurate, with mean sensitivity higher than 80% and mean specificity higher than 90%. The accuracy of FNAB in diagnosing thyroid conditions highly depends on the cytopathologist's expertise and experience and the technical skill of the physician performing the biopsy. In addition, FNAB is highly cost-effective compared with traditional workups that heavily depended on nuclear imaging and ultrasonography. Routine use of FNAB in the evaluation of thyroid nodules can reduce the need for diagnostic thyroidectomy by 20-50% while increasing the yield of cancer diagnoses in thyroid specimens by 1545%. When FNAB of a thyroid nodule provides adequate cellular material for analysis, the specimen can be assigned into one of several different diagnostic classifications. In an effort to improve the communication and clarity of thyroid cytopathology, the National Cancer Institute convened a conference in 2007 to address the current status of FNAB of thyroid nodules. This conference developed a consensus for terminology known as the Bethesda System for Reporting Thyroid Cytopathology. The recommended thyroid FNAB diagnostic categories in this system include benign, atypia of undetermined significance, follicular neoplasm, suspicious for malignancy, malignancy, and nondiagnostic.[12] The respective risk of malignancy associated with each diagnostic category is as follows: Benign - < 1% Atypia (AUS) - 5-10% Follicular neoplasm - 20-30% Suspicious for malignancy - 50-75% Malignant - 100% The main weakness of FNAB involves hypocellular aspirates and aspirates with high follicular cellularity. Hypocellular aspirates may be observed in cystic nodules, or they may be related to biopsy technique. The addition of ultrasonography to guide FNAB sometimes reduces technical errors. Furthermore, ultrasonographyguidance combined with on-site verification of the adequacy of the specimen by a cytotechnologist or a pathologist is likely to reduce the rate of nondiagnostic specimens. See the image below

emedicine.medscape.com/article/127491-ov erv iew

4/8

12/27/12

Thy roid Nodule

Histologic pattern of a mildly differentiated follicular thyroid carcinoma (250 X). Image courtesy of Professor Pantaleo Bufo at University of Foggia, Italy.

Aspirates characterized by high follicular cellularity suggest follicular neoplasm; however, FNAB cannot be used reliably to distinguish a benign follicular neoplasm from a malignant neoplasm. In addition, aspirates that are highly cellular with Hrthle cells can be observed with benign or malignant Hrthle-cell neoplasms and with some cases of Hashimoto thyroiditis.[13] Advances in cytologic analysis may increase the predictive value of FNAB of thyroid nodules in the future. For example, the incorporation of immunocytochemical studies, as well as genetic and molecular profiling of aspirates, may improve the accuracy of minimally invasive diagnostic techniques. In those cytpoathologic classifications where risk of malignancy is relatively indeterminate (Atypia of undetermined significance, follicular neoplasm), improvment in the assessment of the risk of malignancy might be achieved by viewing the cytopathologic results in the context of ultrasonographic characteristics suspicious for malignancy. An Italian study compared the effectiveness of FNAB with that of fine-needle nonaspiration biopsy (FNNAB) in the evaluation of thyroid nodules.[14] The 2 techniques were performed on the same 104 patients who were known to have a uninodular or multinodular goiter. No statistically significant difference was found between the adequacy of samples obtained through FNAB and those collected through FNNAB in the diagnosis of colloid, follicular, or malignant nodules. The only significant difference was in the percentage of samples yielding inadequate results (16.3% and 5.8% for FNAB and FNNAB, respectively). The authors suggested that the frequency of inadequate samples was lower for FNNAB because the technique allows better-quality specimens to be collected. Otherwise, the investigators found both techniques to be useful and cost-effective. Ultrasonography-guided FNAB has become increasingly more common. Clinicians need adequate sampling during biopsies to provide an accurate diagnosis and to avoid repeating the procedure. Insufficient experience with the technique of ultrasonography-guided FNAB is an important factor in the yield of this procedure. One study found, not surprisingly, that physicians who have more experience in performing ultrasonography-guided FNAB have lower rates of inadequate samples.[15] Although the inexperienced group had smaller size nodules, this probably does not affect the results given the obvious difference in competency rates.

Management of Thyroid Nodules

In addition to the clarification of terminology in cytopathologic reporting, the Bethesda conference also established a consensus for the indications to perform FNAB of thyroid nodules, as well as post-FNAB managment options. The current state of the art in thryoid FNAB is nicely outlined in a review by Layfield et al.[16] The most important routine aspects of the diagnostic evaluation of solitary thyroid nodules include thorough history-taking and physical examination, measurement of the serum TSH level, ultrasound-imaging, and FNAB of the nodule. Subsequent management of a solitary thyroid nodule largely depends on the diagnosis from FNAB. Using the Bethesda system, the follicular neoplasm, suspicious for malignancy, and malignant classifications each warrant surgical consultation. Patients with follicular cytopathology on FNAB should be referred to a surgeon because 20-30% of such nodules are malignant. Exceptions may be made in the case of malignant lymphoma, which is typically not managed surgically, and in cases of anaplastic carcinoma, in which surgical intervention may be futile. For the atypia of undetermined significance category, management options include the following: Repeat FNAB in 3-6 months; if repeat ultrasonography-guided biopsy is again atypical, surgical consultation is warranted Surgical consultation if, in addition to atypia, worrisome characteristics on ultrasound are also noted, such as hypoechogenicity, irregular borders, calcifications, or hypervascularity.{Ref13}
5/8

12/27/12

Thy roid Nodule

Nodules classified as benign can be safely followed with ultrasound at 6-18 month intervals with further intervention based on imaging features such as increased growth. Most thyroid nodules associated with benign cytopathology on FNAB can be managed without routine surgical referral, provided that adequate follow-up is possible. Although the incidence of false-negative results with FNAB is low, some physicians recommend repeat FNAB for confirmation 6-12 months after an initial diagnosis of a benign lesion or if the characteristics of the nodule change on follow-up examination. When a benign diagnosis is confirmed, referral to a surgeon is reasonable for patients with symptoms, such as dysphagia or discomfort, or concerns about cosmesis. When findings from the aspirate are nondiagnostic, repeat the aspiration, possibly with ultrasonographic guidance. Nodules for which aspirates are repeated nondiagnostic may ultimately require surgical management.[17]

Special Considerations
Incidentally discovered thyroid nodules
Advances in imaging technology have increased the potential for the incidental discovery of nonpalpable thyroid nodules. When the history and physical findings result in a low index of suspicion for malignancy, periodic followup evaluation with high-resolution ultrasonography is appropriate. Specific guidelines regarding such evaluation have not been established, but findings have raised concern that the incidence of malignancy in nonpalpable nodules may approach that of palpable nodules. For this reason, if sequential sonograms (eg, obtained at 6-mo intervals) reveal an increase in nodular size, ultrasonography-guided FNAB may be appropriate, even if the nodule remains nonpalpable.

Autonomously functioning thyroid nodules

Patients with solitary thyroid nodules associated with suppressed TSH levels, with overt or subclinical hyperthyroidism, do not require routine FNAB. In such cases, the patient may be referred to an endocrinologist to discuss iodine-131 treatment versus surgical intervention.

Contributor Information and Disclosures

Author Steven K Dankle, MD Clinical Associate Professor, Department of Otolaryngology, Medical College of Wisconsin Steven K Dankle, MD is a member of the following medical societies: American Academy of OtolaryngologyHead and Neck Surgery, American Medical Association, and State Medical Society of Wisconsin Disclosure: Nothing to disclose. Specialty Editor Board Steven R Gambert, MD Professor of Medicine, Johns Hopkins University School of Medicine; Director of Geriatric Medicine, University of Maryland Medical Center and R. Adams Cowley Shock Trauma Center Steven R Gambert, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physician Executives, American College of Physicians, American Geriatrics Society, Association of Professors of Medicine, Endocrine Society, and Gerontological Society of America Disclosure: Nothing to disclose. Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Medscape Salary Employment Don S Schalch, MD Professor Emeritus, Department of Internal Medicine, Division of Endocrinology, University of Wisconsin Hospitals and Clinics
emedicine.medscape.com/article/127491-ov erv iew

12/27/12

University of Wisconsin Hospitals and Thy roid Nodule Clinics Don S Schalch, MD is a member of the following medical societies: American Diabetes Association, American Federation for Medical Research, Central Society for Clinical Research, and Endocrine Society Disclosure: Nothing to disclose. Mark Cooper, MBBS, PhD, FRACP Head, Diabetes & Metabolism Division, Baker Heart Research Institute, Professor of Medicine, Monash University Disclosure: Nothing to disclose. Chief Editor George T Griffing, MD Professor of Medicine, St Louis University School of Medicine George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation Disclosure: Nothing to disclose.

References
1. Mazzaglia PJ. Surgeon-Performed Ultrasound in Patients Referred for Thyroid Disease Improves Patient Care by Minimizing Performance of Unnecessary Procedures and Optimizing Surgical Treatment. World J Surg. Feb 4 2010;[Medline]. 2. Gates JD, Benavides LC, Shriver CD, et al. Preoperative thyroid ultrasound in all patients undergoing parathyroidectomy?. J Surg Res. Dec 4 2008;[Medline]. 3. Mendelson AA, Tamilia M, Rivera J, et al. Predictors of malignancy in preoperative nondiagnostic biopsies of the thyroid. J Otolaryngol Head Neck Surg. Jun 2009;38(3):395-400. [Medline]. 4. Park M, Shin JH, Han BK, et al. Sonography of thyroid nodules with peripheral calcifications. J Clin Ultrasound. May 13 2009;[Medline]. 5. Hong YJ, Son EJ, Kim EK, et al. Positive predictive values of sonographic features of solid thyroid nodule. Clin Imaging. March - April 2010;34(2):127-133. [Medline]. 6. Sun Y, Fang S, Dong H, et al. Correlation between osteopontin messenger RNA expression and microcalcification shown on sonography in papillary thyroid carcinoma. J Ultrasound Med. Jun 2011;30(6):765-71. [Medline]. 7. Can AS. Cost-effectiveness comparison between palpation- and ultrasound-guided thyroid fine-needle aspiration biopsies. BMC Endocr Disord. May 16 2009;9:14. [Medline]. [Full Text]. 8. Heston TF, Wahl RL. Molecular imaging in thyroid cancer. Cancer Imaging. Jan 20 2010;10(1):1-7. [Medline]. 9. Vriens D, de Wilt JH, van der Wilt GJ, Netea-Maier RT, Oyen WJ, de Geus-Oei LF. The role of [(18) F]-2fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: Systematic review and meta-analysis of the literature. Cancer. Mar 22 2011;[Medline]. 10. Deandreis D, Al Ghuzlan A, Auperin A, et al. Is (18)F-Fluorodeoxyglucose-PET/CT Useful for the Presurgical Characterization of Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytology?. Thyroid. Feb 2012;22(2):165-72. [Medline]. 11. Kundel A, Zarnegar R, Kato M, et al. Comparison of microarray analysis of fine needle aspirates and tissue specimen in thyroid nodule diagnosis. Diagn Mol Pathol. Mar 2010;19(1):9-14. [Medline]. 12. Cibas ES, Ali SZ. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. Nov 2009;132(5):658-65. [Medline].
emedicine.medscape.com/article/127491-ov erv iew 7/8

2009;132(5):658-65. [Medline]. 13. Raparia K, Min SK, Mody DR, et al. Clinical outcomes for "suspicious" category in thyroid fine-needle aspiration biopsy: patient's sex and nodule size are possible predictors of malignancy. Arch Pathol Lab Med. May 2009;133(5):787-90. [Medline]. 14. Romitelli F, Di Stasio E, Santoro C, et al. A comparative study of fine needle aspiration and fine needle non-aspiration biopsy on suspected thyroid nodules. Endocr Pathol. Summer 2009;20(2):108-13. [Medline]. 15. Gursoy A, Anil C, Erismis B, Ayturk S. Fine-needle aspiration biopsy of thyroid nodules: comparison of diagnostic performance of experienced and inexperienced physicians. Endocr Pract. Nov-Dec 2010;16(6):986-91. [Medline]. 16. Layfield LJ, Cibas ES, Gharib H, Mandel SJ. Thyroid aspiration cytology: current status. CA Cancer J Clin. Mar-Apr 2009;59(2):99-110. [Medline]. 17. Gul K, Ozdemir D, Korukluoglu B, et al. Preoperative and postoperative evaluation of thyroid disease in patients undergoing surgical treatment of primary hyperparathyroidism. Endocr Pract. Jan-Feb 2010;16(1):7-13. [Medline]. 18. Hershman JM, Cheng SY, Gianoukakis AG. Update in thyroidology 2010. J Clin Endocrinol Metab. Jan 2011;96(1):9-14. [Medline]. 19. Ceresini G, Corcione L, Morganti S, et al. Ultrasound-guided fine-needle capillary biopsy of thyroid nodules, coupled with on-site cytologic review, improves results. Thyroid. May 2004;14(5):385-9. [Medline]. 20. Chammas MC, Gerhard R, de Oliveira IR, et al. Thyroid nodules: evaluation with power Doppler and duplex Doppler ultrasound. Otolaryngol Head Neck Surg. Jun 2005;132(6):874-82. [Medline]. 21. Feld S, Garcia M. AACE/AME Guidelines: American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. American Association of Clinical Endocrinologists. Available at http://www.aace.com/pub/pdf/guidelines/thyroid_nodules.pdf. Accessed March 31, 2006. 22. Harvey HK. Diagnosis and management of the thyroid nodule. An overview. Otolaryngol Clin North Am. Apr 1990;23(2):303-37. [Medline]. 23. Li QS, Chen SH, Xiong HH, et al. Papillary thyroid carcinoma on sonography. Clin Imaging. March - April 2010;34(2):121-6. [Medline]. 24. Sabel MS, Staren ED, Gianakakis LM, et al. Effectiveness of the thyroid scan in evaluation of the solitary thyroid nodule. Am Surg. Jul 1997;63(7):660-3; discussion 663-4. [Medline]. 25. Singer PA. Evaluation and management of the solitary thyroid nodule. Otolaryngol Clin North Am. Aug 1996;29(4):577-91. [Medline]. Medscape Reference 2011 WebMD, LLC 26. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. Feb 1 1997;126(3):226-31. [Medline]. 27. Ying AK, Huh W, Bottomley S, et al. Thyroid cancer in young adults. Semin Oncol. Jun 2009;36(3):25874. [Medline].

emedicine.medscape.com/article/127491-ov erv iew

8/8